Researchers found that participants who received cooking education showed improvements in eating more vegetables, fewer carbohydrates, and lower A1C levels. The study also highlighted the importance of addressing food insecurity in diabetes management.
A study published in PAIN Reports found that individuals with opioid use disorder (OUd) experience greater central sensitization, leading to worse quality of life. Central sensitization refers to abnormal pain processing in the brain and spinal cord, causing people to suffer more from pain.
Researchers identify key features of a gene mutation responsible for 15-20% of melanomas, establishing a link between the frequency of specific NRAS mutations and spontaneous melanoma formation. The study could help pinpoint early events required for melanoma formation and develop targeted treatments.
Researchers at Ohio State University Wexner Medical Center have discovered a new molecular drug target to treat cancer, VEGF-A, which can increase expression of dopamine D2 receptors on endothelial cells to stop blood vessel growth and spread diseases like colon cancer and ovarian hyperstimulation syndrome.
Researchers say expanded inquiries can save lives by identifying vulnerable individuals who may not be reporting suicidal ideation. Tailoring assessments to individual situations can help medical professionals uncover hidden risks and prevent tragedies.
A new study found that nearly one-third of older adult female survivors of colorectal, endometrial, and ovarian cancer experience quality-of-life-impacting challenges with physical activity due to chronic lower extremity lymphedema. The researchers urge the medical community to include regular lymphedema assessments in survivorship care.
A new study published in Circulation finds that vaping has a significant and long-term cardiovascular effect on adolescent males, reducing heart function over time. In contrast, female mice exposed to e-cigarette aerosol showed no significant changes in heart function or levels of the enzyme CYP2A5, which breaks down nicotine.
A study led by Ohio State University Wexner Medical Center finds that Black patients with dilated cardiomyopathy have a higher risk of family members being affected. The research analyzed data from 1,220 patients and their relatives, revealing that 39% of Black patients had at least one first-degree family member with the condition.
A study by Ohio State University Wexner Medical Center analyzed years of life lost due to unintentional drug overdose among adolescents (13-19) and young adults (20-39) in the US. The findings suggest a significant burden of overdose-related mortality in this age group, highlighting the need for targeted interventions.
Researchers found that 48% of patients experienced complete or partial response to pembrolizumab treatment, with two-thirds experiencing clinical response. The study suggests a potential for curative intent in patients with recurrent or metastatic uterine cancer.
A new study developed by researchers at Ohio State University Wexner Medical Center found that a simple, self-administered test can identify early signs of dementia sooner than the most commonly used office-based standard cognitive test. The Self-Administered Gerocognitive Examination (SAGE test) accurately identified patients with mil...
A new breath test developed by Ohio State researchers can identify COVID-19 infections in critically ill patients with high accuracy. The non-invasive technology uses nanosensors to detect specific biomarkers in exhaled breath, allowing for rapid screening and exclusion of non-infected patients.
A new study at Ohio State University's Comprehensive Cancer Center is using rapid autopsies to gather biological samples after death to better understand how cancer cells overcome different treatments. This approach has already led to novel findings about drug resistance mechanisms, including the recent approval of a targeted therapy f...
Researchers found that tailored mobile messaging reduced waterpipe tobacco smoking in young adults by 49% after six weeks. The intervention, which included personalized messages and visual cues, was more effective than an untailored message for reducing frequency of use.
A phase 2 clinical trial found that ibrutinib is a safe and effective treatment option for patients with relapsed or variant forms of hairy cell leukemia. The study, conducted at Ohio State University Wexner Medical Center, showed improved cancer control for this high-risk patient group.
A new study found that up to 38.6% of colon cancer patients with a hereditary cancer syndrome may be undetected by current universal tumor-screening methods. Researchers recommend implementing multi-gene panel testing as part of the standard care for all colorectal cancer patients.
A new study suggests that CDK4 and CDK6 inhibitors can improve immune-cell therapies for treating recurrent ER-positive metastatic breast cancer. The study found that these inhibitors cause breast tumors to secrete chemokines that attract T cells, improving patients' response to cancer immunotherapies.
Researchers at Ohio State University Comprehensive Cancer Center identified distinct mutational and molecular changes in four SCLC subtypes, providing new insights into treatment resistance. The findings suggest that subtyping patients before systemic therapy could play a role in drug development and therapy selection.
Researchers at Ohio State University suggest that an oral drug currently used to treat neuromuscular diseases could help prevent a common form of skin cancer caused by UVB radiation. The study found that the neurotransmitter dopamine can stop the development and progression of certain UVB-induced precancerous squamous skin cancers.
Researchers at Ohio State University discovered a new compound called BC1618 that blocks Fbxo48 and increases Ampk function, improving insulin responses in obese mice. The findings build on previous research to understand protein degradation and may lead to the development of a new class of diabetes drugs.
A mouse study found that gabapentin can prevent harmful structural changes in the injured spinal cords of mice, block cardiovascular changes and immune suppression. This could lead to improved quality of life for individuals living with spinal cord injuries.
A new study reveals that older minority cancer patients with poor social determinants experience negative surgical outcomes, including higher complication rates and mortality. Researchers suggest integrating vulnerability assessments into national standard of care models to improve outcomes.
A new therapeutic PD-1 cancer vaccine has been shown to be safe and effective in an animal study, activating both B- and T-cell functions to promote tumor clearance. The vaccine is targeted to block signaling pathways crucial for tumor growth and maintenance, offering a promising approach to immunotherapy.
Preliminary results from two large clinical trials investigating a new PD-1-based immune therapy for metastatic cervical cancer suggest improved response rates and potential new treatment options. The trials involved over 150 patients with recurrent or metastatic cervical cancer and tested the combination of balstilimab and zalifrelimab.
Researchers at Ohio State University have discovered that RNA nanoparticles exhibit elastic and rubbery properties, enabling them to target tumors by slipping through tumor blood vessels. The particles are also excreted from the body quickly via urine, reducing toxicity.
Researchers at Ohio State University Comprehensive Cancer Center have found that molecular characteristics can refine prognostic recommendations for AML patients under age 60. The study detected mutations in several categories, which were associated with better or worse outcomes and may help improve treatment choices.
Researchers at Ohio State University found that spinal cord injuries in mice cause an acquired bone marrow failure syndrome contributing to chronic immune dysfunction. The study also discovered a potential treatment using the FDA-approved drug Plerixafor to mobilize cells from the bone marrow niche and restore immune function.
A new testing method has shown promise in rapidly identifying radiation sickness based on biomarkers measured through a single drop of blood. The test uses microRNAs to quantify the actual radiation dose absorbed, allowing for early and real-time identification of the condition to enable timely clinical interventions.
Researchers at Ohio State University found that blocking an enzyme used by glioblastoma cells to store fats may be a new way to treat the deadly disease. This approach could also apply to other types of cancers that use lipid droplets for energy.
A new study led by Ohio State University researchers has identified a protein within immune cells called PCBP1 that helps shape optimal immune responses to cancer. Higher PCBP1 activity promotes cytotoxic T-cell functions, while lower levels trigger the expression of factors that suppress cancer immune responses.
Researchers at Ohio State University will investigate the short- and long-term effects of e-cigarettes on youth, including their impact on brain, lungs, and heart. The project aims to provide answers on effective regulations and cessation methods to help youth quit vaping.
Researchers at Ohio State University developed RNA nanoparticles to deliver chemotherapeutic drugs paclitaxel and camptothecin, increasing their water solubility and targeting tumor cells. The nanoparticles showed precise drug loading and retention of anti-tumor activity with minimal toxicity.
Researchers at Ohio State University Comprehensive Cancer Center discover a direct connection between thrombin and TGF-b1, a cytokine promoting tumor progression and suppressing immune responses. Blocking this mechanism prevents tumor resistance to immunotherapy and increases tumor-infiltrating immune cells.
Researchers at Ohio State University Wexner Medical Center suggest a new approach to treating advanced, progressing bile duct cancer. The study found that adding an mTOR inhibitor may re-sensitize tumor cells to FGFR inhibitors in patients who develop resistance to these agents.
A new study strengthens the link between vitamin E acetate and EVALI (e-cigarette or vaping product use-associated lung injury), finding it in BAL fluid from 48 of 51 EVALI patients but not healthy individuals. The CDC analyzed samples from 16 states and compared them to 99 healthy individuals.
Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, has been approved by the FDA for first-line therapy in chronic lymphocytic leukemia (CLL) and small cell lymphoma (SML). The drug works by permanently binding to BTK, halting cancer cell growth signals.
Researchers aim to increase colorectal cancer screening and follow-up care among underserved individuals in Appalachia through a multi-institutional $5.7 million grant. The goal is to improve guideline-recommended screenings and healthcare services, particularly in rural communities where trust is a barrier.
Researchers discovered Hedgehog signaling shuts down chemokine secretion by tumor-associated macrophages, limiting CD8 T-cell infiltration. Blocking hedgehog pathway reverses process, promoting CD8 T-cell infiltration into tumor microenvironment.
Researchers at Ohio State University Wexner Medical Center report a measurable increase in inflammation after four weeks of e-cig use without nicotine or flavors. The study suggests that even short-term usage can result in inflammatory changes at a cellular level, a concern as vaping usage is rapidly outpacing scientific understanding.
A new clinical trial found that a cost-effective generic medication, spironolactone, is just as effective as the more expensive drug eplerenone in preserving cardiovascular function in boys with Duchenne muscular dystrophy. The study also showed stabilization of kidney and lung function, with no serious side effects.
Researchers at Ohio State University have made significant breakthroughs in gene replacement therapy for Niemann-Pick type A disease, demonstrating its safety and therapeutic effects in nonhuman primates and mouse models. The treatment has shown a 'bystander effect', preventing motor and memory impairment and increasing survival rates.
Researchers at Ohio State University College of Medicine have identified a metabolic process in the heart that, if treated, could prevent or slow the progression of heart failure. By normalizing a reactive fat compound called acyl-CoA, the hearts retained their ability to burn fat and generate energy.
Researchers found that clusterin protein is strongly related to insulin resistance, increased cardiovascular disease risk, and high blood pressure in obese patients. The study also linked clusterin to fatty liver disease and mortality.
Researchers at Ohio State University Wexner Medical Center found that papaverine inhibits mitochondrial respiration and sensitizes model tumors to radiation. The study suggests that modifying the papaverine molecule could lead to a new class of radiosensitizing drugs with fewer side effects.
A new study published in JAMA Surgery found that breast cancer patients who undergo mastectomy with or without immediate reconstruction tend to be less satisfied than expected with their physical and sexual health post-surgery. Women who choose immediate reconstruction overestimated their satisfaction with appearance, while those who d...
Researchers developed a liquid biopsy test to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer. The study found that 64% of patients had more than 10% tumor DNA, correlated with poor survival outcomes.
Researchers at Ohio State University have developed a novel RNA nanotechnology to decorate exosomes for effective cancer therapy. The technology uses antibody-like RNA nanoparticles to deliver siRNA specifically to cancer cells, overcoming the challenge of delivering therapeutics directly to tumor cells.
Researchers at Ohio State University Wexner Medical Center identified a substance called Gdf-15, released by pancreatic cancer cells, that protects them from immune cell macrophages. GDF-15 inhibits nitric oxide and tumor necrosis factor production in macrophages, allowing tumor cells to survive and grow.
Preclinical studies demonstrate onalespib's effectiveness in inhibiting HSP90, reducing cell-survival proteins and tumor growth. The agent shows promise as a single treatment or in combination with temozolomide for glioblastoma patients.
Researchers at Ohio State University Wexner Medical Center have discovered a DNA-level biomarker that can predict overall survival for patients with anaplastic astrocytoma, a rare form of brain cancer. The study found that MGMT promoter methylation status is significantly associated with overall survival outcomes.